This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaatz, G. W.
Right arrow Articles by Rybak, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaatz, G. W.
Right arrow Articles by Rybak, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 254-256, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis

Glenn W. Kaatz,1,2,3,* Susan M. Seo,1,2 Jeffrey R. Aeschlimann,3,4 Heather H. Houlihan,3,4 Reneé-Claude Mercier,3,4 and Michael J. Rybak1,3,4

Department of Internal Medicine, Division of Infectious Diseases, School of Medicine,1 Department of Veteran's Affairs Medical Center,2 and College of Pharmacy and Allied Health Professions,3 Wayne State University, and The Anti-Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center,4 Detroit, Michigan 48201

Received 29 August 1997/Returned for modification 21 October 1997/Accepted 10 November 1997

Trovafloxacin is a new fluoronaphthyridone chemically and functionally related to members of the fluoroquinolone class of antimicrobial agents. The in vivo efficacy of the drug was compared with that of vancomycin by using the rabbit model of left-sided endocarditis. Rabbits infected with either a nafcillin-susceptible or -resistant test strain were treated with trovafloxacin (13.3 mg/kg of body weight every 12 h) or vancomycin (25 mg/kg of body weight every 8 h) for 4 days. In comparison with untreated controls, both antimicrobial agents effectively cleared bacteremia and significantly reduced bacterial counts in vegetations and tissues of animals infected with either test strain. No resistance to trovafloxacin emerged in test strains during therapy. We conclude that in this model trovafloxacin is as efficacious as vancomycin is and may serve as a viable alternative to vancomycin for use in humans with similar infections.

* Corresponding author. Mailing address: Department of Internal Medicine, Division of Infectious Diseases, Wayne State University School of Medicine, C3690 Detroit VA Medical Center, 4646 John R, Detroit, MI 48201. Phone: (313) 576-4487. Fax: (313) 576-1112. E-mail: gkaatz{at}juno.com.

Antimicrobial Agents and Chemotherapy, February 1998, p. 254-256, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Vaudaux, P., Francois, P., Bisognano, C., Schrenzel, J., Lew, D. P. (2002). Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 1503-1509 [Abstract] [Full Text]  
  • Hershberger, E., Coyle, E. A., Kaatz, G. W., Zervos, M. J., Rybak, M. J. (2000). Comparison of a Rabbit Model of Bacterial Endocarditis and an In Vitro Infection Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 44: 1921-1924 [Abstract] [Full Text]  
  • Backo, M., Gaenger, E., Burkart, A., Chai, Y. L., Bayer, A. S. (1999). Treatment of Experimental Staphylococcal Endocarditis Due to a Strain with Reduced Susceptibility In Vitro to Vancomycin: Efficacy of Ampicillin-Sulbactam. Antimicrob. Agents Chemother. 43: 2565-2568 [Abstract] [Full Text]  
  • Amorena, B., Gracia, E., Monzon, M., Leiva, J., Oteiza, C., Perez, M., Alabart, J.-L., Hernandez-Yago, J. (1999). Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J Antimicrob Chemother 44: 43-55 [Abstract] [Full Text]  
  • Entenza, J. M., Vouillamoz, J., Glauser, M. P., Moreillon, P. (1999). Efficacy of Trovafloxacin in Treatment of Experimental Staphylococcal or Streptococcal Endocarditis. Antimicrob. Agents Chemother. 43: 77-84 [Abstract] [Full Text]  
  • Kim, Y. S., Liu, Q., Chow, L. L., Chambers, H. F., Täuber, M. G. (1998). Comparative Efficacy of Trovafloxacin in Experimental Endocarditis Caused by Ciprofloxacin-Sensitive, Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 42: 3325-3327 [Abstract] [Full Text]  
  • Bayer, A. S., Li, C., Ing, M. (1998). Efficacy of Trovafloxacin, a New Quinolone Antibiotic, in Experimental Staphylococcal Endocarditis Due to Oxacillin-Resistant Strains. Antimicrob. Agents Chemother. 42: 1837-1841 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»